
Aureus
Stage
Other Investors | AliveRevenue
$0000About Aureus
Aureus develops market analytics tools designed for mobility, cloud transformations, enterprise content management and collaboration. The company's tools offer planning and implementation of search through business data, enterprise cloud transformations and predictive analysis. It is based in Centennial, Colorado.
Aureus Patents
Aureus has filed 1 patent.
The 3 most popular patent topics include:
- Customer experience
- Electronic trading systems
- Financial data vendors

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/29/2020 | Customer experience, Market data, Financial markets, Electronic trading systems, Financial data vendors | Application |
Application Date | 12/29/2020 |
---|---|
Grant Date | |
Title | |
Related Topics | Customer experience, Market data, Financial markets, Electronic trading systems, Financial data vendors |
Status | Application |
Latest Aureus News
Sep 13, 2023
September 12, 2023 Credit: NIAID Staphylococcus aureus is a gram-positive bacteria that causes a wide variety of clinical diseases. Infections caused by this pathogen are common both in community-acquired and hospital-acquired settings. Infections can be life-threatening if the bacteria enter the bloodstream, causing sepsis. Now, researchers led by the Peter Doherty Institute for Infection and Immunity analyzed the genetic profiles of more than 1,300 staph strains and uncovered what makes the bacterium so dangerous when it enters the blood. “Outcomes of severe bacterial infections are determined by the interplay between host, pathogen, and treatments,” the researchers wrote. “While human genomics has provided insights into host factors impacting Staphylococcus aureus infections, comparatively little is known about S. aureus genotypes and disease severity. Building on the hypothesis that bacterial pathoadaptation is a key outcome driver, we developed a genome-wide association study (GWAS) framework to identify adaptive mutations associated with treatment failure and mortality in S. aureus bacteremia (1,358 episodes). Our research highlights the potential of vancomycin-selected mutations and vancomycin minimum inhibitory concentration (MIC) as key explanatory variables to predict infection severity.” By combining this data with patient and antibiotic information, the researchers found that, while patient factors are critical in determining mortality risks, specific genes are linked to antibiotic resistance, along with the bacteria’s ability to linger in the blood, evading antibiotics and the immune system. “To the best of our knowledge, this is one of the first times that the method we used, called a genome-wide association study (GWAS), has been applied to delve into the role of bacterial genomes, host factors, and antibiotics on the course of staphylococcal sepsis,” said Stefano Giulieri, MD, PhD, a clinician-researcher at the Doherty Institute and first author of the paper. “In GWAS, scientists scan the genome of a big collection of bacteria to look for tiny changes (mutations) that show up more often in strains with a certain characteristic, such as antibiotic resistance. Mutations with a strong statistical link are precious clues to figuring out how bacteria acquire attributes that are important for patient outcomes. “Our study uncovered a deeper understanding of the intricate genetic dynamics underlying severe Golden staph infections. It highlights the potential of combining bacterial whole-genome sequencing, clinical data, and sophisticated statistical genomics to discover clinically relevant bacterial factors that influence infection outcomes.” “By revealing the genes responsible for antibiotic resistance in Golden staph, our GWAS is pointing the scientific community to clearer targets for the development of effective solutions to treat Golden staph bloodstream infections,” said University of Melbourne professor Ben Howden, director of the Microbiological Diagnostic Unit (MDU) Public Health Laboratory at the Doherty Institute and co-senior author of the paper. “This knowledge has the potential to shape and enhance our ability to tackle these persistent infections. As bacterial genomes become increasingly available in the clinical routine, we inch closer to customized therapeutic strategies, where treatments will be tailored to the unique genetic makeup of the infecting strain, rather than treating everyone in the same way.”
Aureus Frequently Asked Questions (FAQ)
Where is Aureus's headquarters?
Aureus's headquarters is located at 12835 E Arapahoe Rd, Centennial.
What is Aureus's latest funding round?
Aureus's latest funding round is Other Investors.
Who are the investors of Aureus?
Investors of Aureus include Connecticut Innovations.
Who are Aureus's competitors?
Competitors of Aureus include ThoughtSpot and 4 more.
Compare Aureus to Competitors

WhizAI provides a cognitive insights platform for life sciences. It helps users to get answers to their business questions by asking questions via voice, text on the web, and mobile. It incorporates the language and data of life sciences, enabling it to answer complex questions from a vast database. The company was founded in 2017 and is based in Somerset, New Jersey.

Sisense provides business intelligence tools. The company offers solutions such as data visualization, data modeling, git integration, and more. It serves the healthcare, financial, manufacturing, and other sectors. It was founded in 2004 and is based in New York, New York.

Skopai has developed a platform to gather neutral, complete and real-time information on any start-up in the world.

Promethium provides an augmented data management platform. It offers real-time access to enterprise data and answers without moving data. It also offers artificial intelligence (AI) and machine learning (ML)- driven automation software to ensure all data is used to deliver information. The company serves the retail industry, healthcare industry, retail & wholesale, and more. It was founded in 2018 and is based in Menlo Park, California.

Hypersonix provides artificial intelligence (AI)-powered autonomous analytics software designed for consumer commerce. It identifies risks and opportunities to maximize and optimize profits. It optimizes pricing, inventory, and competitor Intelligence for eCommerce profit growth. The company was founded in 2018 and is based in San Jose, California.

vPhrase offers a tool Phrazor operates as a reporting automation and business intelligence platform. It provides the elimination of data misinterpretation, data storytelling, analytics, pre-built reporting templates, and more. The primary clients are banking, finance, media and entertainment, retail, and logistics. It was formerly known as Phrazor. founded in 2015 and is based in Mumbai, India.